reports
Pineapple Resources Berhad: 1 director
A director at Pineapple Resources Berhad bought 266,950 shares at 0.700MYR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
TC Energy to issue first quarter 2024 results on May 3 and hold annual...
TC Energy to issue first quarter 2024 results on May 3 and hold annual and special meeting of common shareholders on June 4 CALGARY, Alberta, April 16, 2024 (GLOBE NEWSWIRE) -- TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will release its first quarter 2024 financial results on Friday, May 3, 2024 pre-market and hold its 2024 annual and special meeting of common shareholders on Tuesday, June 4, 2024, at 8 a.m. MDT / 10 a.m. EDT. First quarter 2024 financial resultsFrançois Poirier, TC Energy President and Chief Executive Officer, Joel Hunter, Executive Vice-President...
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics Provides SAB-142 Trial Update MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of serum sickness thus far. In October 2023, SAB rec...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targe...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver....
Director/PDMR Shareholding
Director/PDMR Shareholding TORONTO, ONTARIO, April 16, 2024 (GLOBE NEWSWIRE) -- (“Amaroq Minerals” or the “Company”) Director/PDMR Shareholding - Notification of Transactions of Directors/Persons Discharging Managerial Responsibilities (PDMRs) TORONTO, ONTARIO – April 16, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ) announces that on April 15, 2024, it was informed that Livermore Partners LLC, a company in which David Neuhauser, Non-Executive Director of Amaroq Minerals, is Managing Director, acquired a total of 19,200 common shares of no par value in the Company. This ...
Edison issues review on Tetragon Financial Group (TFG): FY23 growth dr...
Edison Investment Research Limited Edison issues review on Tetragon Financial Group (TFG): FY23 growth driven by idiosyncratic factors 16-Apr-2024 / 12:07 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 16 April 2024 Edison issues review on Tetragon Financial Group (TFG): FY23 growth driven by idiosyncratic factors Tetragon Financial Group (Tetragon) posted a 6.4% net asset value (NAV) per share total return in US dollar terms in FY23. Tetragon’s returns normally have a low correlation with broader markets, and therefore its FY23 pe...
- Felix Fischer
Lucror Analytics - Morning Views Latam
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar. To request full and unrestricted access to Lucror’s research and analytics platform, please visit
Divfex Berhad: 1 director
A director at Divfex Berhad sold 4,870,000 shares at 0.133MYR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
KRM22: 1 director
A director at KRM22 bought 100,000 shares at 25p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
Zhongzhi Pharmaceutical Holdings Limited: 1 director
A director at Zhongzhi Pharmaceutical Holdings Limited bought 2,259,000 shares at 1.170HKD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors - Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience - ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. “We are...
Moody's Ratings downgrades Dongfeng to A3; outlook remains negative
Moody's Ratings has downgraded Dongfeng Motor Group Company Limited's (Dongfeng) issuer rating to A3 from A2, and its Baseline Credit Assessment (BCA) to baa3 from baa2. At the same time, Moody's Ratings has downgraded to A3 from A2 the backed senior unsecured rating on the bonds issued by Dongfen...
Moody's Ratings downgrades Dongfeng to A3; outlook remains negative (C...
穆迪投资者服务公司 1*请注意新闻稿之英文原版已于香港时间4月12日发放穆迪评级下调东风汽车的评级至A3；展望仍为负面 香港，2024年4月12日—中文新闻稿为英文的翻译件。如有出入，以英文稿为准。穆迪评级已将东风汽车集团股份有限公司 (东风汽车) 的发行人评级从A2下调至A3，其基础信用评估 (BCA) 从baa2下调至baa3。与此同时，穆迪评级将东风汽车间接全资子公司东风汽车 (香港) 国际有限公司所发行债券的有支持高级无抵押债务评级从A2下调至A3。该债券由东风汽车提供不可撤销及无条件的担保。评级展望仍为负面。穆迪评级副总裁/高级信用评级主任何卓荣表示：“下调评级及负面展望反映了东风汽...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.